You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Approval provided for Angelini’s cenobamate

Angelini Pharma has revealed that cenobamate has been reimbursed for adjunctive treatment of focal onset seizures with or without secondary generalisation among adult patients with epilepsy.